In brief, the findings of this study substantiate the hypothesis that targeting S1PR4 may be a promising therapeutic approach for non-eosinophilic phenotypes (refractory or ICS-insensitive) of asthma in clinical settings. This evidence concerns the gene S1PR4 and asthma.